Next-generation CAR T cells
Dr John Maher discusses the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours.
Dr John Maher, founder and Chief Scientific Officer of Leucid Bio, responds to questions about how to overcome the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours and how the clinical stage biotech company is making strides towards this goal.
